RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+5.38%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.43B
AUM Growth
+$1.43B
(+17%)
Cap. Flow
+$174M
Cap. Flow
% of AUM
12.16%
Top 10 Holdings %
Top 10 Hldgs %
28.58%
Holding
96
New
13
Increased
36
Reduced
31
Closed
4
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$34.5M |
| 2 |
Cencora
COR
|
$19.8M |
| 3 |
McKesson
MCK
|
$17.2M |
| 4 |
Intuitive Surgical
ISRG
|
$16.3M |
| 5 |
Abbott
ABT
|
$15M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$24.9M |
| 2 |
AbbVie
ABBV
|
$14.3M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12.2M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$9.46M |
| 5 |
Glaukos
GKOS
|
$7.55M |
Sector Composition
| 1 | Healthcare | 96.33% |
| 2 | Industrials | 0.98% |
| 3 | Technology | 0.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Intuitive Surgical
ISRG
$158B
| $21.4M | 1.49% |
29,000
+22,000
| +314% | +$16.3M |
|
27
Merck
MRK
$210B
| $20.8M | 1.45% |
270,000
-74,020
| -22% | -$5.71M |
|
28
Zimmer Biomet
ZBH
$20.8B
| $20.8M | 1.45% |
130,000
+65,000
| +100% | +$10.4M |
|
29
Becton Dickinson
BDX
$54.3B
| $20.7M | 1.44% |
85,000
+40,000
| +89% | +$9.73M |
|
30
Thermo Fisher Scientific
TMO
$183B
| $20.5M | 1.43% |
45,000
+17,550
| +64% | +$8.01M |
|
31
Bristol-Myers Squibb
BMY
$96.7B
| $20.5M | 1.43% |
325,000
-15,000
| -4% | -$947K |
|
|
32
Cencora
COR
$57.2B
| $19.8M | 1.38% |
+167,957
| New | +$19.8M |
|
33
Cooper Companies
COO
$13.3B
| $19.2M | 1.34% |
50,000
-5,000
| -9% | -$1.92M |
|
34
Alnylam Pharmaceuticals
ALNY
$58.6B
| $19.1M | 1.33% |
135,000
+23,300
| +21% | +$3.29M |
|
35
MacroGenics
MGNX
$121M
| $17.4M | 1.21% |
545,160
-79,840
| -13% | -$2.54M |
|
|
36
McKesson
MCK
$85.9B
| $17.2M | 1.2% |
+88,000
| New | +$17.2M |
|
37
Esperion Therapeutics
ESPR
$490M
| $16.6M | 1.16% |
592,225
| – | – |
|
38
Baxter International
BAX
$12.1B
| $16M | 1.12% |
190,000
-15,000
| -7% | -$1.27M |
|
|
ITCI
39
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15.5M | 1.08% |
457,778
-42,222
| -8% | -$1.43M |
|
40
Neurocrine Biosciences
NBIX
$13.5B
| $15.1M | 1.05% |
155,000
+5,000
| +3% | +$486K |
|
41
HCA Healthcare
HCA
$95.4B
| $14.1M | 0.98% |
75,000
| – | – |
|
|
BHVN
42
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $13.7M | 0.96% |
200,419
-34,581
| -15% | -$2.36M |
|
|
43
BioMarin Pharmaceuticals
BMRN
$11.3B
| $13.6M | 0.95% |
180,000
-330,000
| -65% | -$24.9M |
|
|
AERI
44
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $13.4M | 0.93% |
750,000
-100,000
| -12% | -$1.79M |
|
45
Apellis Pharmaceuticals
APLS
$3.51B
| $11.6M | 0.81% |
270,000
| – | – |
|
46
LivaNova
LIVN
$3.09B
| $11.4M | 0.8% |
155,000
-35,000
| -18% | -$2.58M |
|
|
SGEN
47
DELISTED
Seagen Inc. Common Stock
SGEN
| $11.1M | 0.77% |
80,000
+15,000
| +23% | +$2.08M |
|
48
Xencor
XNCR
$594M
| $10.1M | 0.71% |
235,000
-24,341
| -9% | -$1.05M |
|
49
Sangamo Therapeutics
SGMO
$161M
| $9.59M | 0.67% |
765,000
-56,888
| -7% | -$713K |
|
|
50
Regeneron Pharmaceuticals
REGN
$59.8B
| $9.46M | 0.66% |
20,000
-20,000
| -50% | -$9.46M |
|